Strategic Partnerships CrystecPharma has recently announced a strategic partnership with Joel Hi-Tech, signaling openness to collaboration and co-development opportunities. This presents a sales angle to offer complementary process optimization, scaling support, or joint development programs for mSAS technology.

Award-Driven credibility Multiple industry recognitions, including Women in Pharma and Innovation of the Year, bolster credibility with potential customers. Use these accolades to approach biotech and pharma firms seeking validated, award-winning process enhancements and biotech stabilization capabilities.

Global engagement Active participation in major industry events such as BIO International Convention and CPHI Frankfurt indicates a broad, globally minded sales target. Leverage event momentum to schedule executive briefings, pilot discussions, and introductions to prospective pharmaceutical manufacturers seeking improved dissolution, bioavailability, and delivery options.

Technology focus mSAS and crystal/particle engineering capabilities directly address poorly soluble drugs, bioavailability, and alternative delivery routes including inhalation. Target small to mid-size pharma and biotech pipelines with solubility challenges, offering reduced development risk and faster path to clinic.

Growth signals Revenue range and growing recognition, alongside a lean team (11-50 employees) with high-impact technology, suggest a fit for licensing, contract R&D, and milestone-based collaborations. Pursue pilot projects, scalable manufacturing support, and technology licensing discussions with strategic partners seeking advanced crystallization and solvent elimination solutions.